CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
Sulfonylureadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00321321
NCT00321321Phase 2Completed
CompareCT.gov

Phase 2 Study of The Beta Cell Responsiveness to GIP With and Without Sulfonylurea in Patients With Type 2 Diabetes

University Hospital, Gentofte, Copenhagen·interventional·Posted May 3, 2006·Updated Jul 16, 2015

In Brief

A Phase 2 clinical trial evaluating Sulfonylurea for Diabetes Mellitus, Type 2. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The investigators hypothesize that the impaired insulinotropic effect of the incretin hormone GIP may be due to inadequate sensitization and ATP induced closure of beta cell K-ATP channels. By closing the channels through the use of sulfonylurea (SU) we hope to restore the insulinotropic effect of GIP.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesDenmark
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 3, 2006
Enrollment StartMay 1, 2006
Primary CompletionMar 1, 2007
Study CompletionApr 1, 2007
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 20.2 years ago

Interventions

Sulfonylureadrug